-
公开(公告)号：EP4261217A1
公开(公告)日：2023-10-18
申请号：EP22917642.5
申请日：2022-09-22
发明人： ZHANG, Jiancun , ZHANG, Lijun , ZHOU, Yiqian , CHEN, Jiafeng , ZHANG, Jufu , LI, Suyong , LIU, Yanhui , GUO, Chen , TANG, Wanjun , WU, Feng , HE, Xiaoxi , GUO, Qi , CHEN, Huixuan , WANG, Kun , LI, Deyao
IPC分类号： C07H19/20 , C07H1/00 , A61K31/7125 , C12N15/10 , C12P19/34
摘要： The present invention relates to compounds for RNA capping and uses thereof, which belong to the technical field of genetic engineering. Compounds of formula I can result in high levels of capping efficiency, and the capped mRNA exhibits increased expression.
-
公开(公告)号：EP4261217A9
公开(公告)日：2023-12-27
申请号：EP22917642.5
申请日：2022-09-22
发明人： ZHANG, Jiancun , ZHANG, Lijun , ZHOU, Yiqian , CHEN, Jiafeng , ZHANG, Jufu , LI, Suyong , LIU, Yanhui , GUO, Chen , TANG, Wanjun , WU, Feng , HE, Xiaoxi , GUO, Qi , CHEN, Huixuan , WANG, Kun , LI, Deyao
IPC分类号： C07H19/20 , C07H1/00 , A61K31/7125 , C12N15/10 , C12P19/34
摘要： The present invention relates to compounds for RNA capping and uses thereof, which belong to the technical field of genetic engineering. Compounds of formula I can result in high levels of capping efficiency, and the capped mRNA exhibits increased expression.
-
公开(公告)号：EP3805234A1
公开(公告)日：2021-04-14
申请号：EP19806418.0
申请日：2019-05-22
发明人： ZHANG, Jiancun , ZOU, Qingan , CHEN, Yanwei , KANG, Ning , ZHANG, Lijun , HU, Yang , ZHANG, Jufu
IPC分类号： C07D513/04 , A61K31/41 , A61P35/00 , A61P9/00 , A61P29/00 , A61P25/28 , A61P37/00 , A61K31/433
摘要： The present invention provides a novel heteroaromatic compound as an Autotaxin (ATX) inhibitor, a pharmaceutical composition comprising the compound, and a use thereof in a treatment of a disease with a pathological feature of Autotaxin (ATX) overexpression in a mammal, wherein the compound is according to formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, or mixture thereof; wherein each of R 1 , Ar 1 , Ar 2 , Ar 3 , W, Y, Z, and Cy is defined in the present invention.
-
公开(公告)号：EP4242211A1
公开(公告)日：2023-09-13
申请号：EP21891247.5
申请日：2021-11-15
发明人： ZOU, Qingan , ZHANG, Jiancun , CHEN, Yanwei , ZHANG, Lijun , KANG, Ning , GUO, Chen
IPC分类号： C07D513/04 , C07D519/00 , A61K31/433 , A61K31/454 , A61K31/438 , A61P35/00 , A61P3/00 , A61P9/00
摘要： The present invention provides a novel imidazothiazole compound as an Autotaxin (ATX) inhibitor, a pharmaceutical composition comprising the compound, and uses thereof in a treatment of a disease with a pathological feature of Autotaxin (ATX) overexpression in a mammal, wherein the compound has a structure of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, or mixture thereof; wherein each of R 1a , R 1c , R 2 , R 3 , R 6 , Cy, Y, Z, and t is defined as described in the present invention.
-
公开(公告)号：EP4238966A1
公开(公告)日：2023-09-06
申请号：EP21885135.0
申请日：2021-10-26
发明人： LI, Deyao , ZHOU, Yiqian , GUO, Qi , YOU, Huajin , ZHANG, Lijun , ZHANG, Jiancun
IPC分类号： C07D333/10 , A61K31/381 , A61P25/16 , A61P25/14 , A61P25/24
摘要： The present invention provides a novel tetrahydronaphthalene compound, or a stereoisomer, a solvate, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, and a use of the compound or the composition for preparing a medicament in prevention and/or treatment of a central nervous system disease, wherein the compound has a structure of formula (I),
wherein, each of X, Y, Z, W and R is defined as described in the present invention.-
6.发明公开
公开(公告)号：EP3450427A1
公开(公告)日：2019-03-06
申请号：EP17788790.8
申请日：2017-04-27
发明人： ZHANG, Jiancun , LI, Deyao , LI, Hong , WANG, Kun , LIU, Yan , WU, Yan , TANG, Xing , SONG, Jianbo
IPC分类号： C07D211/56 , A61K31/451 , A61K9/19 , A61P31/16
摘要： The present invention relates to a cyclohexene derivative or pharmaceutically acceptable salt thereof and application thereof, which belongs to the technical field of pharmaceutical technology. The cyclohexene derivative of formula I or pharmaceutically acceptable salt thereof is a new broad-spectrum anti-influenza compound, having a great inhibiting effect on influenza viruses, specifically, it has a high activity to virus strains which is drug-resistant to Oseltamivir, and may be used as a broad-spectrum anti-influenza NA inhibitor effective to Tamiflu drug-resistance, for treating the flu caused by influenza viruses, thereby it is a new broad-spectrum anti-influenza drug.
-
公开(公告)号：EP3401315A1
公开(公告)日：2018-11-14
申请号：EP16883420.8
申请日：2016-12-22
发明人： ZHANG, Jiancun , ZOU, Qingan , CHEN, Yanwei
IPC分类号： C07D413/12 , C07D417/14 , C07D471/08 , C07D413/14 , A61P1/16 , A61P31/20 , A61P35/00 , A61P29/00
CPC分类号： C07D413/12 , C07D413/14 , C07D417/14 , C07D471/08 , Y02P20/55
摘要： The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC 50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
